EpimAb Biotherapeutics

EpimAb Biotherapeutics, Inc. is an innovative international biotechnology company with research and development centers and GMP production bases in Shanghai and Suzhou, respectively. The company focuses on the research and development of innovative bioproducts using its proprietary bispecific antibody technology platform, FIT-Ig®. Based on the FIT-Ig® platform technology, EpimAb Biotherapeutics is developing a series of original bispecific antibody products targeting immuno-oncology and other fields with high clinical demand. EpimAb Biotherapeutics is also achieving strategic development and product diversification of the platform through global technology licensing, co-development, and various other forms.